Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2014; 20(26): 8471-8481
Published online Jul 14, 2014. doi: 10.3748/wjg.v20.i26.8471
Published online Jul 14, 2014. doi: 10.3748/wjg.v20.i26.8471
Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation
Stacey J Coleman, Jennifer Watt, Prabhu Arumugam, Leonardo Solaini, Elisabeta Carapuca, Mohammed Ghallab, Richard P Grose, Hemant M Kocher, Centre for Tumour Biology, Barts Cancer Institute - a CR-UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom
Jennifer Watt, Prabhu Arumugam, Leonardo Solaini, Hemant M Kocher, Barts and the London HPB Centre, The Royal London Hospital, Barts Health NHS Trust, London EC1M 6BQ, United Kingdom
Author contributions: Coleman SJ designed and wrote the paper; Watt J, Arumugam P, Solaini L, Carapuca E, Ghallab M and Grose RP contributed equally to the writing of the paper; Kocher HM made final amendments of the paper and approval of the version to be published.
Correspondence to: Hemant M Kocher, MS, MD, FRCS, Centre for Tumour Biology, Barts Cancer Institute - a CR-UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom. h.kocher@qmul.ac.uk
Telephone: +44-20-78823579 Fax: +44-20-78823884
Received: October 18, 2013
Revised: January 15, 2014
Accepted: April 1, 2014
Published online: July 14, 2014
Processing time: 268 Days and 20.4 Hours
Revised: January 15, 2014
Accepted: April 1, 2014
Published online: July 14, 2014
Processing time: 268 Days and 20.4 Hours
Core Tip
Core tip: Pancreatic cancer carries a terrible prognosis, as the fourth most common cause of cancer death in the Western world. One of the reasons no effective treatment has been developed in the past decade may in part, be explained by the influences exerted by the tumour microenvironment. The tumour stroma cross-talk in pancreatic cancer can influence chemotherapy delivery and response rate. Organotypic models of pancreatic cancer allow new therapies that can target the cancer, the stromal compartment or both to be tested in a model that mirrors the in vivo situation and can help improve patient prognosis.